358 related articles for article (PubMed ID: 33906643)
1. Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.
Umemura M; Suda G; Tsukamoto S; Ebata K; Takahash S; Sasaki T; Nakajima S; Hirata K; Ozasa M; Takano M; Katagiri M; Sakamoto N
BMC Infect Dis; 2021 Apr; 21(1):389. PubMed ID: 33906643
[TBL] [Abstract][Full Text] [Related]
2. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
[TBL] [Abstract][Full Text] [Related]
3. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Poordad F; Pol S; Asatryan A; Buti M; Shaw D; Hézode C; Felizarta F; Reindollar RW; Gordon SC; Pianko S; Fried MW; Bernstein DE; Gallant J; Lin CW; Lei Y; Ng TI; Krishnan P; Kopecky-Bromberg S; Kort J; Mensa FJ
Hepatology; 2018 Apr; 67(4):1253-1260. PubMed ID: 29152781
[TBL] [Abstract][Full Text] [Related]
4. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.
Yu ML; Tai CM; Mo LR; Kuo HT; Huang CF; Tseng KC; Lo CC; Bair MJ; Wang SJ; Huang JF; Yeh ML; Chen CT; Tsai MC; Huang CW; Lee PL; Yang TH; Huang YH; Chong LW; Chen CL; Yang CC; Hung CH; Yang SS; Cheng PN; Hsieh TY; Hu JT; Wu WC; Cheng CY; Chen GY; Zhou GX; Tsai WL; Kao CN; Lin CL; Wang CC; Lin TY; Lin CL; Su WW; Lee TH; Chang TS; Liu CJ; Dai CY; Chen CY; Kao JH; Lin HC; Chuang WL; Peng CY
Hepatol Int; 2024 Apr; 18(2):461-475. PubMed ID: 38246899
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.
Ruwayni AA; AlObary EE; Alyahya KM
Saudi Med J; 2024 Jan; 45(1):34-39. PubMed ID: 38220241
[TBL] [Abstract][Full Text] [Related]
6. [Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].
Sánchez Suárez MM; Martín Roldán A; Cantudo Cuenca MR
Rev Esp Quimioter; 2024 Jun; 37(3):283-284. PubMed ID: 38638059
[No Abstract] [Full Text] [Related]
7. Diffuse large B-cell lymphoma as an extra-hepatic manifestation of hepatitis C and co-infection of helicobacter pylori: A case report.
Kumar N; Abbasi A; Hussain SM; Mahmood A; Talreja K
J Pak Med Assoc; 2024 May; 74(5):980-983. PubMed ID: 38783451
[TBL] [Abstract][Full Text] [Related]
8. Lessons of the month 2: Ocular manifestations and complications of hepatitis C infection.
Fang SL; Teo L; Loo CY; Li JW; Santosa A
Clin Med (Lond); 2021 Jul; 21(4):e417-e419. PubMed ID: 35192489
[TBL] [Abstract][Full Text] [Related]
9.
Minamimoto R; Fayad L; Vose J; Meza J; Advani R; Hankins J; Mottaghy F; Macapinlac H; Heinzel A; Juweid ME; Quon A
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2883-2893. PubMed ID: 33909086
[TBL] [Abstract][Full Text] [Related]
10. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
Goyal RK; Jain P; Nagar SP; Le H; Kabadi SM; Davis K; Kaye JA; Du XL; Wang M
Leuk Lymphoma; 2021 Jun; 62(6):1325-1334. PubMed ID: 33966583
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Surgical Resection and Chemotherapy Versus Chemotherapy Alone for the Treatment of Isolated Primary Adrenal Lymphoma: A Retrospective Cohort Study of 16 Consecutive Patients.
Illuminati G; Nardi P; Fratini C; Pasqua R; Giordano C; Girolami M; Carboni F
Anticancer Res; 2021 May; 41(5):2647-2652. PubMed ID: 33952495
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Balasubramanian S; Wang S; Major C; Hodkinson B; Schaffer M; Sehn LH; Johnson P; Zinzani PL; Carey J; Shreeve SM; Sun S; Gerecitano J; Vermeulen J; Staudt LM; Wilson W
Br J Haematol; 2021 Jul; 194(1):83-91. PubMed ID: 33942292
[TBL] [Abstract][Full Text] [Related]
13. Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.
Salcedo Betancourt JD; Garcia Valencia OA; Becerra-Gonzales VG; Carias Martinez KG; Chapman J; Yanchenko N; Ladino MA
Clin Nephrol Case Stud; 2021; 9():49-53. PubMed ID: 33928009
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
[TBL] [Abstract][Full Text] [Related]
15. Collision Tumor Comprising Primary Malignant Lymphoma and Adenocarcinoma in the Ascending Colon.
Kataoka J; Nitta T; Ota M; Fujii K; Ishii M; Senpuku S; Ueda Y; Tsuchimoto Y; Takeshita A; Miyatake J; Ishibashi T
Case Rep Gastroenterol; 2021; 15(1):379-388. PubMed ID: 33976615
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline-containing
Gao HF; Wu Z; Lin Y; Song XY; Cao Y; Chen QJ; Zhang G; Fu P; Liu Z; Zhang LL; Yang CQ; Yang M; Zhu T; Ji F; Li JQ; Cheng MY; Wang K
Ther Adv Med Oncol; 2021; 13():17588359211009003. PubMed ID: 33959195
[TBL] [Abstract][Full Text] [Related]
17. Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.
Eertink JJ; Burggraaff CN; Heymans MW; Dührsen U; Hüttmann A; Schmitz C; Müller S; Lugtenburg PJ; Barrington SF; Mikhaeel NG; Carr R; Czibor S; Györke T; Ceriani L; Zucca E; Hutchings M; Kostakoglu L; Loft A; Fanti S; Wiegers SE; Pieplenbosch S; Boellaard R; Hoekstra OS; Zijlstra JM; de Vet HCW
Blood Adv; 2021 May; 5(9):2375-2384. PubMed ID: 33944897
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Daniele G; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Zaccarelli E; Nardin M; Bogani G; Distefano M; Greggi S; Piccirillo MC; Fossati R; Giannone G; Arenare L; Gallo C; Perrone F; Pignata S
Int J Gynecol Cancer; 2021 Jun; 31(6):875-882. PubMed ID: 33931498
[TBL] [Abstract][Full Text] [Related]
19. What if COVID-19 affects the child: which weapons and how to use them.
Anedda L; Bianchini L; Cuzzolin L; Finco G; Fanos V; Marcialis MA
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(8):3325-3337. PubMed ID: 33928620
[TBL] [Abstract][Full Text] [Related]
20. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
